alzheon, Author at Alzheon | Preserving Future Memories - Page 14 of 21

About alzheon

This author has not yet filled in any details.
So far alzheon has created 202 blog entries.

23 Oct, 2017

Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer’s Disease

alzheon2019-09-23T12:10:48-04:00October 23rd, 2017|

12 Oct, 2017

Alzheon to Make Presentations on ALZ-801 and its Anti-Oligomer Mechanism at the 10th Clinical Trials on Alzheimer’s Disease Congress

alzheon2024-08-02T13:22:41-04:00October 12th, 2017|

20 Sep, 2017

Alzheon to Make Keynote and Featured Presentations at Upcoming Scientific and Industry Conferences

alzheon2024-08-05T18:29:09-04:00September 20th, 2017|

17 Jul, 2017

Alzheon updates on precision medicine approach to treating AD

alzheon2019-09-23T12:10:48-04:00July 17th, 2017|Tags: thepharmaletter|

17 Jul, 2017

ALZ-801 Mechanism of Action: Stoichiometry of Beta Amyloid Anti-Oligomer Effect, PK/PD, and Clinical Dose Selection for Confirmatory Phase 3 Program in Alzheimer’s Disease

alzheon2019-09-23T12:10:49-04:00July 17th, 2017|

17 Jul, 2017

Alzheon Presents New Data for Lead Candidate ALZ-801 on Novel MOA and Long-Term Clinical Efficacy at the Alzheimer’s Association International Conference

alzheon2024-08-02T10:28:55-04:00July 17th, 2017|

23 Jun, 2017

Alzheon says data backs potential of Alzheimer’s candidate

alzheon2019-09-23T12:10:49-04:00June 23rd, 2017|Tags: PMLiVE|

22 Jun, 2017

Alzheon to Present Novel Molecular Mechanism of Action and Long Term Clinical Efficacy Data for Lead Candidate ALZ-801 at the Alzheimer’s Association International Conference

alzheon2024-08-02T11:15:45-04:00June 22nd, 2017|

22 Jun, 2017

Clinical Effects Of Tramiprosate In APOE4/4 Homozygous Patients With Mild Alzheimer’s Disease Suggest Disease Modification Potential

alzheon2019-09-23T12:10:49-04:00June 22nd, 2017|

22 Jun, 2017

Alzheon Publishes New Analyses Showing Clinical Benefit of Tramiprosate in APOE4/4 Homozygous Patients at the Mild Stage of Alzheimer’s Disease; Clinical Effects Suggest Disease Modification Potential and Align with Preclinical Effects on Beta Amyloid Oligomer Formation

alzheon2024-08-02T11:26:03-04:00June 22nd, 2017|